`571-272-7822
`
`
`
`
`
`
`Paper 14
`Entered: December 5, 2016
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`DR. REDDY’S LABORATORIES, LTD. AND DR. REDDY’S
`LABORATORIES, INC.,
`
`Petitioner,
`v.
`MONOSOL RX, LLC,
`Patent Owner.
`____________
`
`Case IPR2016-01111
`Patent 8,603,514 B2
`____________
`Before ERICA A. FRANKLIN, TINA E. HULSE, and
`CHRISTOPHER G. PAULRAJ, Administrative Patent Judges.
`
`FRANKLIN, Administrative Patent Judge.
`
`
`DECISION
`Denying Institution of Inter Partes Review
`37 C.F.R. § 42.108
`
`
`
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`
`INTRODUCTION
`I.
`Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc.
`(collectively, “Petitioner”) filed a Petition to institute an inter partes review
`of claims 1–3, 9, 15, 62–65, 69–73, and 75 of U.S. Patent No. 8,603,514 B21
`(Ex. 1001, “the ’514 patent”). Paper 1 (“Pet.”). MonoSol RX, LLC (“Patent
`Owner”) filed a Preliminary Response to the Petition. Paper 10 (“Prelim.
`Resp.”).
`We have jurisdiction under 35 U.S.C. § 314, which provides that an
`inter partes review may not be instituted “unless . . . there is a reasonable
`likelihood that the petitioner would prevail with respect to at least 1 of the
`claims challenged in the petition.” 35 U.S.C. § 314(a).
`Upon considering the Petition and Preliminary Response, we
`determine that the Petitioner has not demonstrated a reasonable likelihood
`that it would prevail in showing the unpatentability of at least one of the
`challenged claims. Accordingly, we decline to institute an inter partes
`review of any challenged claim.
`A.
`Related Proceedings
`Petitioner and Patent Owner identify a number of district court
`proceedings that “may affect or be affected by a decision in the proceeding.”
`Pet. 8–9; Paper 4, 2–3. In particular, both parties identify Reckitt Benckiser
`Pharmaceuticals Inc. v. Watson Laboratories, Inc. et al., C.A. No.1:13-CV-
`01674-RGA (D. Del.) and Reckitt Benckiser Pharmaceuticals Inc. v. Par
`Pharmaceutical, Inc. et al., C.A. No.1:14-CV-00422-RGA (D. Del.),
`
`
`
` 1
`
`
`
`
`
` Issued to Robert K. Yang et al., Dec. 10, 2013.
`2
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`wherein each case included MonoSol Rx among the plaintiffs and for which
`a consolidated trial opinion addressing the ’514 patent was issued on June 3,
`2016. Ex. 2009.
`
`The ’514 Patent (Ex. 1001)
`B.
`The ’514 patent relates to rapidly dissolving films for delivering orally
`administered active ingredients. Ex. 1001, 1:43–44. The films comprise a
`polymer component and active ingredients as taste-masked coated particles
`uniformly distributed throughout the film. Id. at 1:44–47. The Specification
`explains that some film forming techniques suffer from aggregation or
`conglomeration of particles, resulting in a random distribution of film
`components and any actives present in a non-uniform manner. Id. at 2:7–28,
`60–62. Non-uniform film “necessarily prevents accurate dosing.” Id. at
`2:51–52. The Specification explains also that such films would not likely
`meet standards set by the U.S. Federal Drug Administration (“FDA”) for an
`acceptable amount of variation in dosage forms. Id. at 2:38–42. According
`to the Specification, “as required by various world regulatory authorities,
`dosage forms may not vary more than 10% in the amount of active present.”
`Id. at 2:42–45.
`The Specification describes the instant invention as providing “rapid-
`dissolve film products for drug delivery whereby the active agents are taste-
`masked or controlled-release coated particles uniformly distributed
`throughout the film,” wherein the film may be “divided into equally sized
`dosage units having substantially equal amounts of each compositional
`component present.” Id. at 4:27–33. The invention is described as
`particularly advantageous for the pharmaceutical industry because it permits
`“large area films to be initially formed, and subsequently cut into individual
`
`
`
`
`3
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`dosage units without concern for whether each unit is compositionally
`equal” and “contain the proper predetermined amount of drug.” Id. at 4:33–
`42.
`C.
`Illustrative Claim
`Independent claim 1 of the ’514 patent is illustrative and reproduced
`below:
`1. A drug delivery composition comprising:
`(i) a cast film comprising a flowable water-soluble or water
` swellable film-forming matrix comprising one or more
` substantially water soluble or water swellable polymers;
` and a desired amount of at least one active;
` wherein said matrix has a viscosity sufficient to aid in
` substantially maintaining non-self-aggregating uniformity
` of the active in the matrix;
`(ii) a particulate active substantially uniformly stationed in
` the matrix; and
`(iii) a taste-masking agent coated or intimately associated
` with said particulate to provide taste-masking of the
` active;
`wherein the combined particulate and taste-masking agent
` have a particle size of 200 microns or less and said
` flowable water-soluble or water swellable film-forming
` matrix is capable of being dried without loss of substantial
` uniformity in the stationing of said particulate active
` therein; and
`wherein the uniformity subsequent to casting and drying of
` the matrix is measured by substantially equally sized
` individual unit doses which do not vary by more than
` 10% of said desired amount of said at least one active.
`
`Ex. 1001, 67:34–56; (emphasis added to identify dispositive limitation).
`
`
`
`
`
`
`
`4
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`
`The Cited References and Declaration
`D.
`Petitioner relies upon the following references:
`
`
`Bess
`
`Ex. 1004
`
`Ex. 1005
`
`
`Ex. 1006
`
`US Patent No. 7,067,116, issued Jun. 27, 2006
`
`Patent Application Publication No. WO 00/42992,
`published Jul. 27, 2000
`
`Cremer Patent Application Publication No. CA 2,274,910
`A1, issued Jun 25, 1998
`
`
`Petitioner relies also upon the Declaration of Metin Çelik, Ph.D. (Ex.
`1003).
`
`Chen
`
`
`
`The Asserted Grounds of Unpatentability
`E.
`Petitioner challenges the patentability of claims 1–3, 9, 15, 62–65, 69–
`73, and 75 of the ’514 patent on the following grounds (Pet. 12):
`
`Claims Challenged
`1–3, 9, 15, 62–65, 69–73, and 75
`
`Basis
`§ 103
`
`References
`Bess and Chen
`
`1–3, 9, 15, 62–65, 69–73, and 75
`
`§ 103
`
`Chen and Cremer
`
`
`
`
`
` ANALYSIS
`A. Claim Construction
`In an inter partes review, the Board interprets claim terms in an
`unexpired patent according to the broadest reasonable construction in light
`of the specification of the patent in which they appear. 37 C.F.R.
`§ 42.100(b); Cuozzo Speed Techs., LLC v. Lee, 136 S. Ct. 2131, 2142 (2016)
`(affirming applicability of broadest reasonable construction standard to inter
`partes review proceedings). Under that standard, and absent any special
`definitions, we give claim terms their ordinary and customary meaning, as
`
`5
`
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`would be understood by one of ordinary skill in the art at the time of the
`invention. In re Translogic Tech., Inc., 504 F.3d 1249, 1257 (Fed. Cir.
`2007). Any special definitions for claim terms must be set forth with
`reasonable clarity, deliberateness, and precision. In re Paulsen, 30 F.3d
`1475, 1480 (Fed. Cir. 1994).
`Only terms which are in controversy need to be construed, and only to
`the extent necessary to resolve the controversy. Vivid Techs., Inc. v. Am.
`Sci. & Eng’g, Inc., 200 F.3d 795, 803 (Fed. Cir. 1999).
`Petitioner proposes a construction for one claim phrase: “dried
`without the loss of substantial uniformity,” appearing in independent claims
`1 and 62. Pet. 15. According to Petitioner, that claim phrase should be
`construed broadly to mean “any method of drying.” Id. In support of that
`construction, Petitioner asserts only that Patent Owner’s expert witness in a
`co-pending litigation “testified that the claims were not limited to any
`particular form of drying, or any particular drying parameters.” Id.
`Patent Owner correctly notes that Petitioner has not explained why it
`has failed to account for the phrase “without the loss of substantial
`uniformity” in its proposed construction. Prelim. Resp. 8. Further, Patent
`Owner proposes that, under the broadest reasonable construction standard,
`the claim phrase “dried without the loss of substantial uniformity” should be
`given its plain meaning. Id. Based on the record, we agree.
`B. Obviousness over Bess and Chen
`Petitioner contends that claims 1–3, 9, 15, 62–65, 69–73, and 75
`
`would have been obvious over the combination of Bess and Chen. Pet. 27–
`50. Patent Owner disagrees. Prelim. Resp. 11–26.
`
`
`
`
`
`6
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`
`Bess
`1.
`Bess discloses “fast dissolving orally consumable films containing an
`ion exchange resin to mask the taste of a pharmaceutically active agent
`therein.” Ex. 1004, 1:67–2:3. The average particle size of the
`pharmaceutically active agent/resin complexes is about 60 to about 250
`micrometers, and more preferably, between about 55 and about 160
`micrometers, and most preferably between about 60 and 150 micrometers.
`Id. at 11:53–63. Bess teaches that the film may be prepared by combining
`all of the ingredients to form a uniform polymer gel, deaerating the film to
`remove air bubbles, casting the uniform mixture on a suitable substrate, and
`drying the cast mixture to form a film. Id. at 12:4–16.
`2.
`Chen
`Chen discloses a dosage unit comprising a water-soluble hydrocolloid
`and a mucosal surface-coat-forming film that includes an effective dose of
`an active agent. Ex. 1005, 3:30–32. Chen’s film may also include a taste
`modifying agent. Id. at 4:4–5. Chen describes a number of disadvantages
`provided by a variety of prior art dosage forms, including those having
`particle sizes greater than 25 microns. In particular, Chen states, “many
`quick dissolving tablets contain particulates (>25 microns) which leave a
`‘gritty’ and unpleasant taste in the mouth.” Id. at 2:19–20.
`Chen describes forming its film, in one respect, by mixing
`hydrocolloid, dissolved or dispersed in water, to form a homogenous
`formulation. Id. at 15:19–21. Chen explains, “[i]n addition to the active
`agent and the hydrocolloid, any of the ingredients listed above may be added
`and dispersed or dissolved uniformly in the hydrocolloid solution.” Id. at
`15:21–23. Thereafter, the “homogeneous mixture (coating solution) . . . was
`
`
`
`
`7
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`degassed (8) and coated on the non-siliconized side of a polyester film . . .
`and dried under aeration.” Id. at 15:24–28.
`3.
`Analysis
`A conclusion that the claimed subject matter is obvious must be
`supported by evidence, as shown by some objective teaching in the prior art
`or by knowledge generally available to one of ordinary skill in the art that
`would have led that individual to combine the relevant teachings of the
`references to arrive at the claimed invention. See In re Fine, 837 F.2d 1071,
`1074 (Fed. Cir. 1988). Obviousness grounds must be supported with
`“articulated reasoning with some underpinning” and not by “mere
`conclusory statements.” See KSR Int’l Co. v. Teleflex Inc., 550 U.S 398, 418
`(2007).
`Petitioner asserts that Bess and Chen each disclose certain limitations
`shared by independent claims 1 and 62, i.e., a cast film comprising a
`flowable, water-soluble or water swellable film-forming matrix, one or more
`substantially water-soluble or water swellable polymers, at least one
`particulate active to be present in the claimed formulation, and a taste-
`masking agent that is coated or intimately associated with the particulate to
`provide taste-masking of the active. Pet. 28–30.
`With regard to the requirement that “the combined particulate and
`taste-masking agent have a particle size of 200 microns or less,” Petitioner
`asserts that “Chen teaches that small particles are desirable to avoid gritty
`mouth feel” and that “Bess teaches particle sizes of less than 100 microns.”
`Id. at 30. Additionally, Petitioner and its declarant, Dr. Çelik, assert that a
`person of ordinary skill in the art would have been “motivated to decrease
`particle size to reduce settling rate of the suspension.” Id.; Ex. 1003 ¶ 140.
`
`
`
`
`8
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`
`For the claim limitation reciting “the uniformity subsequent to casting
`and drying of the matrix is measured by substantially equally sized
`individual unit doses which do not vary by more than 10% of said desired
`amount of said at least one active,” Petitioner asserts that a person of
`ordinary skill in the art would have recognized that Chen discloses film
`formulations that satisfy the claimed 10% variability limitation. Pet. 30–31.
`According to Petitioner and Dr. Çelik, a person of ordinary skill would have
`understood that Chen’s process of forming its film composition would have
`provided a matrix sufficiently viscous to substantially prevent settling and
`self-aggregation of particulate active ingredients . . . during casting and
`drying.” Id. at 31.
`Further, Petitioner asserts that a person of ordinary skill in the art
`would have recognized that Chen’s films meet the 10% variability limitation
`because Chen used a rotary die to cut the coated and dried sheet. Id. at 31–
`32. According to Petitioner, a person of ordinary skill in the art “would have
`understood that individual doses of pharmaceutical film can only be
`manufactured this way if the film is at least as uniform as the claimed 10%
`limit.” Id. at 32 (citing Ex. 1003 ¶ 101). In support of that assertion, Dr.
`Celik refers to a section of the challenged patent that states, “[c]urrently, as
`required by various world regulatory authorities, dosage forms may not vary
`more than 10% in the amount of active present.” Ex. 1003 ¶ 101; Ex. 1001,
`2:42–45. According to Petitioner and Dr. Celik, “the entire purpose of
`Chen’s process was to make pharmaceutical film drug products that were at
`least at uniform as the 10% limit.” Pet. 32 (citing Ex. 1003 ¶ 101).
`Additionally, Petitioner asserts that data disclosed by Chen would
`have confirmed for a person of ordinary skill in the art that Chen’s films
`
`
`
`
`9
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`were at least as uniform as the claimed 10% variation limitation. Pet. 32.
`To support that assertion, Petitioner refers to Chen’s disclosure of the weight
`and thickness of individual dosage units of film in Example 1, which did not
`contain an active ingredient. Id. According to Petitioner, that data
`indicating a low standard of deviation for those units demonstrates that the
`film was manufactured in a “very uniform manner.” Id. Petitioner refers
`also to Chen’s description of exemplary films containing either sildenafil or
`dextromethorphan as an active agent wherein the individual dosages had less
`than a 10% variance in either the thickness (sildenafil films) or weight
`(dextromethorphan films). Id. at 33–34.
`Additionally, Petitioner relies upon Chen’s data for dissolution tests
`conducted on exemplary films containing one of a variety of active agents.
`Id. According to Petitioner, Chen’s Figure 5 shows the end state in which
`all of the drug has been released and that the final values are clustered within
`the claimed ±10% limit, causing a person of skill in the art to have
`reasonably expected that “Chen’s methods could be used to make films that
`fall within the 10% limit.” Id. (citing Ex. 1005, 23; Ex. 1003 ¶ 103).
`Patent Owner asserts a number of reasons why Petitioner has not
`demonstrated a reasonable likelihood of establishing that a person of skill in
`the art would have found it obvious to combine the teachings of Bess and
`Chen in a manner that yields the claimed invention. Having considered the
`arguments and the evidence, we agree with Patent Owner. In particular, we
`agree with Patent Owner that Petitioner has not established that either Bess
`or Chen teaches or suggests a drug delivery composition wherein the
`uniformity of individual unit doses, subsequent to casting and drying, does
`not vary by more than 10% of the desired amount of at least one active in the
`
`
`
`
`10
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`cast film. PO Resp. 11. For that limitation in its claim chart, Petitioner
`refers to Bess’ description of providing a “uniform gel.” See Pet. 42. Bess,
`however, describes casting that gel on a substrate and drying the cast to
`provide the film. Ex. 1004, 2:14–27. Petitioner has not identified, nor do
`we see, any disclosure in Bess that teaches or suggests any specific degree of
`uniformity regarding the film product at all, and notably not subsequent to
`casting and drying. Nor has Petitioner shown that Bess recognizes a
`potential loss of uniformity with respect to the amount of active ingredient in
`individual unit doses after casting and drying. To the extent that Petitioner
`refers to Bess’ disclosure of the thickness and weight of the film after
`drying, Petitioner has not explained persuasively how those properties
`establish that the desired amount of the active ingredient in the individual
`unit doses does not vary by more than 10%.
`For that same limitation, Petitioner’s claim chart refers to Chen’s
`teaching that viscosity plays a significant role in determining the properties
`of the film. Pet. 42. Petitioner has not shown, however, that Chen teaches
`or suggests that viscosity plays a role in providing a uniform film product or
`that it may aid in achieving the variation limit recited in the challenged
`claims. Petitioner relies also on Dr. Çelik’s testimony that because Chen’s
`matrix has a viscosity range that falls within a range disclosed in the
`challenged patent, a person of skill in the art “would have understood Chen’s
`matrix to be sufficiently viscous to substantially prevent settling and self-
`aggregation of particulate active ingredients . . . during casting and drying.”
`Ex. 1003 ¶ 99. In addition to “generally” disclosing various ranges for the
`viscosity of its matrix, the ’514 patent explains the importance of selecting a
`proper viscosity, and making adjustments to the viscosity “based on the
`
`
`
`
`11
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`selected active depending on the other components within the matrix.” Ex.
`1001, 11:24–37. We note that Dr. Çelik does not discuss any such required
`adjustments in the cited portion of his declaration. Moreover, the ’514
`patent explains that, for example, if one of the other components within the
`matrix is not soluble within the selected solvent, “a proper viscosity may be
`selected to prevent the component from settling which would adversely
`affect the uniformity of the resulting film.” Id. at 11:35–37. In other words,
`although the ’514 patent explains that selecting a proper viscosity is
`important to achieving uniformity in a resulting film, it does not suggest that
`simply providing a film having any viscosity falling within the disclosed
`range will ensure such uniformity.
`Petitioner’s claim chart refers also to Chen’s teaching that ingredients
`may be dispersed uniformly within the gel for the 10% variation limitation.
`Pet. 42. However, Chen’s discussion of dispersing ingredients uniformly
`actually involves dispersing or dissolving ingredients “uniformly in the
`hydrocolloid solution” to provide a “homogenous mixture” that is
`subsequently degassed and coated on a film and dried. Ex. 1005, 15:19–29.
`In other words, Chen is addressing the uniformity and homogeneity of the
`mixture prior to casting and drying. In terms of the resulting dry film, Chen
`characterizes it only as “a glossy, stand alone, self supporting, non-tacky and
`flexible film” that may be die-cut into a single dosage unit. Id. at 15:30–
`16:4.
`Petitioner relies also on Chen’s Figure 5 to establish the 10% variance
`limitation, asserting that Figure 5 “shows low variance in the desired amount
`of the active.” Pet. 42. Dr. Çelik explains that Figure 5 demonstrates the
`time when the amount of drug released from each tested film plateaued,
`
`
`
`
`12
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`indicating near-maximal release, and that the final values for the drug
`release “are clustered within ±10% of 100.” Ex. 1003 ¶ 103. According to
`Dr. Çelik, “[f]rom these data, a person of ordinary skill would reasonably
`have concluded that the films were within the claimed 10% limit.” Id. We
`are unpersuaded. In particular, what is missing from Dr. Çelik’s testimony
`is an explanation of his data analysis. Chen’s Figure 5 is reproduced below:
`Ex. 1005, Fig. 5.
`
`
`Chen’s Figure 5 shows the release profile of four active agents from films
`according to Chen’s Examples 5–8. Ex. 1005, 16:27–28. Chen does not
`discuss the data represented in Figure 5 or otherwise provide it.2 Nor does
`
`
`
` 2
`
` Petitioner asserts that the Board “has found on appeal in three
`reexaminations directed to similar subject matter that Chen discloses
`substantial uniformity.” Pet. 35. As discussed, infra, those decisions did not
`
`13
`
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`Dr. Çelik present his opinion regarding the relevant specific data points
`reflected in Figure 5. Rather, Dr. Çelik opines, in a conclusory fashion, that
`the data shows, despite the unexplained error bars in the figure and lack of
`specific data points provided, that “the final recorded values for the data
`collected . . . fall at or within ‡ 10% of 100% (i.e., 90% to 110%),” and that
`a person of skill in the art would, therefore, conclude that “Chen’s films had
`at least the claimed uniformity.” Ex. 1003, 38 n.7. Because Dr. Çelik has
`not provided a reliable factual basis for his opinion on this matter, those
`opinions are not entitled to persuasive weight. See Office Patent Trial
`Practice Guide, 77 Fed. Reg. 48,756, 48763 (Aug. 14, 2012) (a declaration
`expressing an opinion of an expert without disclosing underlying facts may
`be given no weight).
`
`We remain unpersuaded by Petitioner’s assertion that Chen’s
`disclosure of the thickness and/or weight of films not containing active
`ingredient or of exemplary films comprising an active ingredient suggest
`that Chen’s films satisfy the claimed 10% variation. Pet. 32. Petitioner has
`not explained the relevance of discussing a property of a film that does not
`contain an active ingredient when addressing a claim limitation that relates
`to achieving a uniform amount of an active ingredient in the film.
`Moreover, as discussed regarding Bess, supra, Petitioner has not explained
`how the thickness or weight of a film containing an active ingredient
`provides a person of skill in the art insight into whether individual unit doses
`vary by more than 10% of the desired amount of the active agent.
`
`
`
`squarely address the 10% variation limitation presented in the challenged
`claims.
`
`
`
`14
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`Nor has Petitioner explained persuasively that a skilled artisan would
`
`have understood that individual doses of a pharmaceutical film cut by a
`rotary die can only be manufactured this way if the film does not vary more
`than 10%. Pet. 31–32. Petitioner’s argument and Dr. Celik’s testimony in
`that regard rely upon a statement in the challenged patent that “[c]urrently,
`as required by various world regulatory authorities, dosage forms may not
`vary more than 10% in the amount of active present.” Pet. 32; Ex. 1003 ¶
`101; Ex. 1001, 2:42–45. Petitioner and Dr. Celik acknowledge, however,
`that not all regulatory authorities require that limit. Specifically, Petitioner
`and Dr. Celik recognize that in the United States, “any given dose of the
`drug must have the same amount of active as any other dose, within a
`variance of 15%,” referring to the standard set by the United States Food and
`Drug Administration. Pet. 22; Ex. 1003 ¶ 81. Thus, at best, Petitioner’s
`reliance on the disclosure of the challenged patent regarding the standards
`set by the FDA or “various world regulatory authorities” provides a
`motivation for a person of skill in the art to modify the cited prior art to
`achieve a product film wherein the individual unit doses do not vary by more
`than 15%, or perhaps not more than 10%. However, even if such motivation
`exists, Petitioner has not shown how that the cited prior art or other
`knowledge in the art at the time of the invention would have informed an
`artisan how to reach that goal. As Patent Owner correctly asserts,
`“[r]ecognition of a need does not render obvious the achievement that meets
`that need.” Prelim. Resp. 17 (quoting Cardiac Pacemakers, Inc. v. St. Jude
`Med., Inc., 381 F.3d 1371, 1377 (Fed. Cir. 2004) and Abbott Labs. v.
`Sandoz, Inc., 544 F.3d 1341, 1352 (Fed. Cir. 2008)).
`
`
`
`
`15
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`Insofar as Petitioner asserts that a person of ordinary skill in the art
`
`would have needed only routine experimentation to make films within the
`claimed variance limitation, we are unpersuaded. Pet. 27, 34. In a
`somewhat cursory manner, Petitioner supports that contention by asserting
`that a person of skill in the art “would have understood that mixing, de-
`gassing, viscosity and drying are all important variables to control in order to
`ensure uniformity, and would have been able to make routine adjustments of
`these variables in Chen’s process to meet the 10% limit.” Pet. 34. Dr. Celik
`makes a similar statement in his declaration. Ex. 1003 ¶ 104. However,
`neither statement by Petitioner or Dr. Celik includes a discussion of facts
`allegedly supporting those assertions.
`To the extent Petitioner asserts that “collateral estoppel will
`preclude re-argument” regarding the issue of whether Chen discloses films
`wherein “the uniformity subsequent to casting and drying of the matrix is
`measured by substantially equally sized individual unit doses which do
`not vary by more than 10% of said desired amount of at least one active,”
`as recited by independent claims 1 and 62, that argument is misplaced.
`Pet. 35–38. According to Petitioner, the Board already found that Chen
`discloses that limitation in Appeal 2014-000547, an inter partes
`reexamination of U.S. Patent 7,824,588 B2 (“the ’588 patent”) (Ex. 1038).
`Pet. 35, 37. We disagree. In the ’588 patent decision, because Patent
`Owner did not argue any claims separately, the Board resolved the issue of
`whether Chen met the uniformity requirement based on independent claim
`1 of the ’588 patent. Ex. 1038, 12. Unlike independent claims 1 and 62 of
`the challenged patent, claim 1 of the ’588 patent, as amended, required
`only “substantially uniform content of therapeutic active composition per
`
`
`
`
`16
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`
`unit of film.” Ex. 1038, 4. Thus, the ’588 patent decision did not resolve
`the issue of whether Chen met the 10% variation limit required by the
`challenged patents. Consequently, Petitioner has not shown that the
`instant situation meets the requirements for applying collateral estoppel,
`i.e., issue preclusion, because the issue presented in the ’588 patent
`decision is not identical to the issue presented here, and resolution of the
`issue presented in this case was not essential to the final judgment in the
`’588 patent decision. See In re Freeman, 30 F.3d 1459, 1465 (Fed. Cir.
`1994) (setting forth the four requirements for issue preclusion).3
`For all of the foregoing reasons, we determine that Petitioner has not
`established persuasively that a person of ordinary skill in the art would have
`found it obvious to combine the teachings of Bess and Chen in a manner that
`resulted in a cast film drug delivery system wherein the uniformity
`subsequent to casting and drying the matrix is measured by substantially
`equally sized individual unit doses which do not vary by more than 10% of
`the active agent, as required by independent claims 1 and 62.
`Accordingly, we determine that Petitioner has not demonstrated a
`reasonable likelihood of establishing that it would prevail in showing the
`unpatentability of independent claims 1 and 62, or their respective dependent
`claims, 2–3, 9, 15, 63–65, 69–73, and 75, over Bess and Chen.
`
`
`
` 3
`
` We note that the district court has issued a decision addressing the
`disclosures of Chen and Bess with respect to the ’514 patent. See Ex. 2009.
`We note further that our findings are consistent with those set forth in that
`decision.
`
`
`
`17
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`
` C. Obviousness over Chen and Cremer
`Petitioner contends that claims 1–3, 9, 15, 62–65, 69–73, and 75
`
`would have been obvious over the combination of Chen and Cremer. Pet.
`50–62. Patent Owner disagrees. Prelim. Resp. 26–28.
`1.
`Cremer
`Cremer is directed to a medicament preparation for delivering a drug
`in the buccal cavity. Ex. 1006, Abstract. Cremer describes its preparation as
`a “foil-type” tape comprising an active substance and a binder. Id. at 4.
`According to Cremer, there is “a direct relation existing, by reason of the
`homogeneous thickness, density and width, between a unit of length of the
`tape and the dose of active substance contained therein.” Id.
`2. Analysis
`Petitioner again relies on Chen for the teachings asserted for the
`challenge over Bess and Chen. Pet. 50. Petitioner asserts that, like Chen,
`Cremer teaches a drug delivery composition that comprises a flat, water-
`soluble drug delivery preparation for pharmaceutical actives. Id. Petitioner
`asserts that Cremer teaches that “homogeneous thickness, density and
`width” of a gel will lead to a “direct relation . . . between a unit of length of
`the [film] and the dose of active substance contained therein.” Id. (quoting
`Ex. 1006, 1). Petitioner includes a claim chart referring to the teachings of
`Chen and the above-mentioned teaching of Cremer. Pet. 52–61. According
`to Petitioner, a person of skill in the art would have been motivated to
`achieve a film wherein the uniformity subsequent to casting and drying of
`the matrix, “as measured by substantially-equally sized individual unit
`doses, does not vary by more than 10% of the desired amount of active––to
`satisfy regulatory and manufacturing requirements of low variation in dose–
`
`
`
`
`18
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`–and would have reasonably expected to succeed in doing so.” Id. at 51
`(citing Ex. 1006, 1; Ex. 1003 ¶ 131). Petitioner does not provide any further
`explanation for those assertions or in support of its challenge of claims 1–3,
`9, 15, 62–65, 69–73, and 75 over the combination of Chen and Cremer.
`To the extent that Petitioner relies on Chen and Dr. Celik’s declaration
`in the same manner discussed, supra, regarding Petitioner’s ground
`challenging the claims over Bess and Chen, we are unpersuaded for the same
`reasons discussed regarding that ground. Insofar as Petitioner relies on
`Cremer in combination with Chen to yield the drug delivery compositions of
`the challenged claims, we remain unpersuaded as Petitioner has not
`explained sufficiently what that combination would involve or how the
`combined teachings and/or skill in the art are alleged to support it.
`Accordingly, we determine that Petitioner has not demonstrated a
`reasonable likelihood of establishing that it would prevail in showing the
`unpatentability of claims 1–3, 9, 15, 62–65, 69–73, and 75 over the
`combination of Chen and Cremer.
`
`CONCLUSION
`For the foregoing reasons, we determine that the information
`presented in the Petition does not establish that there is a reasonable
`likelihood that Petitioner would prevail in showing that any of the
`challenged claims are unpatentable.
`IV.
` ORDER
`In consideration of the foregoing, it is hereby ordered that the Petition
`is denied.
`
`
`
`
`
`
`
`19
`
`
`
`IPR2016-01111
`Patent 8,603,514 B2
`
`FOR PETITIONER:
`
`Jeffery Arnold
`Peter Hagerty
`Leslie-Anne Maxwell
`Andrew Ryan
`CANTOR COLBURN LLP
`jarnold@cantorcolburn.com
`phagerty@cantorcolburn.com
`amaxwell@cantorcolburn.com
`ryan@cantorcolburn.com
`
`
`FOR PATENT OWNER:
`
`Harold Fox
`John Abramic
`STEPTOE & JOHNSON